NIH re­jects an­oth­er at­tempt to 'march-in' on Astel­las' prostate can­cer drug over ex­ces­sive price

The Na­tion­al In­sti­tutes of Health has again de­clined to use so-called “march-in” rights to low­er the price of Astel­las and Pfiz­er’s prostate can­cer drug Xtan­di …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER